ISB Expands Use of Lumera Technology to Cover Biomarker Detection Technology | GenomeWeb
NEW YORK (GenomeWeb News) — Lumera has expanded its agreement with the Institute for Systems Biology to focus on detection methods for a cancer biomarker array, the Bothell, Wash.-based company said today.
 
The expanded agreement builds on a February 2005 pact in whic ISB agreed to test Lumera's ProteomicProcessor system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.